博瑞医药公告，全资子公司博瑞制药（苏州）有限公司收到国家药品监督管理局签发的“碘普罗胺注射液”《药品注册证书》。碘普罗胺注射液用于诊断用药，2022年至2024年国内销售额分别为11.88亿元、13.58亿元和15.09亿元。该药品获批上市将丰富公司制剂产品管线，但受行业政策、市场环境等影响，对公司经营业绩的影响尚存在不确定性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.